MFG Investments LLC Purchases 668 Shares of Eli Lilly and Company $LLY

MFG Investments LLC acquired a new stake in shares of Eli Lilly and Company (NYSE:LLY – Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm acquired 668 shares of the company’s stock, valued at approximately $773,000. Eli Lilly and Company makes up 0.9% of MFG Investments LLC’s portfolio, making the stock its 29th biggest position.

Several other large investors have also recently modified their holdings of LLY. Torren Management LLC lifted its holdings in Eli Lilly and Company by 357.1% in the third quarter. Torren Management LLC now owns 32 shares of the company’s stock valued at $37,000 after buying an additional 25 shares during the period. Marshall & Sterling Wealth Advisors Inc. raised its holdings in Eli Lilly and Company by 60.0% during the first quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock worth $37,000 after buying an additional 15 shares during the last quarter. Foresight Capital Management Advisors Inc. bought a new position in Eli Lilly and Company in the 3rd quarter valued at about $49,000. AlphaCentric Advisors LLC purchased a new position in shares of Eli Lilly and Company during the first quarter valued at approximately $42,000. Finally, Caitlin John LLC bought a new stake in shares of Eli Lilly and Company in the 2nd quarter worth $64,000. Institutional investors own 82.53% of the company’s stock.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the sale, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. This represents a 10.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the completion of the transaction, the executive vice president owned 4,137 shares of the company’s stock, valued at approximately $5,802,225.24. This trade represents a 54.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 18,500 shares of company stock worth $22,970,770. Corporate insiders own 0.14% of the company’s stock.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: A report says Cantor Fitzgerald raised its price target to $1,600 from $1,440 and kept an “overweight” rating, adding to analyst optimism. Cantor Fitzgerald price-target update
• Positive Sentiment: Lilly advanced a next-generation obesity treatment into a Phase 3 study. Further progress could strengthen its pipeline beyond current weight-loss drugs, although the report provides limited trial details. Lilly advances Phase 3 obesity study
• Positive Sentiment: ETFs reportedly bought about $105 million of LLY shares on Nov. 2, suggesting institutional fund demand that may support the stock. ETF purchases of Lilly shares
• Positive Sentiment: In a challenge brought by Lilly, the National Advertising Division recommended that Good Life Meds stop or revise certain claims about compounded tirzepatide products. The recommendation could help Lilly contest marketing by compounded-drug competitors. Advertising claims recommendation
• Neutral Sentiment: EVP Anat Hakim sold 5,000 shares under a pre-arranged Rule 10b5-1 plan. The sale is notable, though the planned nature makes it less clear as a signal about the company’s outlook. Insider sale report
• Negative Sentiment: Recent commentary questions the quality and durability of Lilly’s growth, citing possible one-off revenue benefits and lower realized prices. With expectations and valuation elevated, any deceleration could pressure the shares. Revenue growth quality concerns

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $1,418.14 on Thursday. The business’s 50 day simple moving average is $1,207.75 and its 200 day simple moving average is $1,097.85. Eli Lilly and Company has a 12 month low of $850.51 and a 12 month high of $1,449.68. The company has a market cap of $1.33 trillion, a price-to-earnings ratio of 46.03, a PEG ratio of 1.76 and a beta of 0.40. The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The company reported $7.48 EPS for the quarter, beating analysts’ consensus estimates of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The firm had revenue of $24.40 billion for the quarter, compared to analysts’ expectations of $22.58 billion. During the same quarter in the prior year, the firm earned $7.02 EPS. The business’s revenue for the quarter was up 38.6% compared to the same quarter last year. Sell-side analysts forecast that Eli Lilly and Company will post 35.70 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Friday, November 13th. Eli Lilly and Company’s payout ratio is currently 22.46%.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on LLY shares. Royal Bank Of Canada lifted their target price on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock an “outperform” rating in a research report on Friday, October 30th. Cantor Fitzgerald upped their target price on Eli Lilly and Company from $1,440.00 to $1,600.00 and gave the company an “overweight” rating in a report on Monday. Argus increased their price target on Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the company a “buy” rating in a research report on Friday, October 30th. Sanford C. Bernstein reiterated an “outperform” rating and set a $1,450.00 price target on shares of Eli Lilly and Company in a report on Monday, October 26th. Finally, Truist Financial reissued a “buy” rating and issued a $1,612.00 price objective (up from $1,376.00) on shares of Eli Lilly and Company in a research report on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $1,404.14.

Check Out Our Latest Stock Report on Eli Lilly and Company

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.

Featured Stories

• Five stocks we like better than Eli Lilly and Company
• Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
• Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
• onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
• Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.